JournalsHub
.online
Find My Journal
SS

Slobodan Srećković

Kliničko Bolnički Centar Zvezdara RS

14
Publications
155
Citations
4
H-Index
3
i10-Index
8.38
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial OA
Silvio Danese, Remo Panaccione, Brian G. Feagan, Anita Afzali, David T. Rubin +95 more
˜The œLancet. Gastroenterology & hepatology 2023
65
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) OA
Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, Silvio Danese, Maria Kłopocka +28 more
Gastroenterology 2024
59
P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study OA
B E Sands, Stephen B. Hanauer, J F Colombel, William Sandborn, S Schreiber +19 more
Journal of Crohn s and Colitis 2023
20
Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY) OA
Jean–Frédéric Colombel, William J. Sandborn, Stefan Schreiber, Silvio Danese, Maria Kłopocka +28 more
Journal of Crohn s and Colitis 2025
4
Infliximab Rescue in Acute Severe Ulcerative Colitis Complicated by Clostridium Difficile Infection: A Case Series OA
Srdjan Marković, Marijana Jankovic, Ana Kalaba, Branimir Zogovic, Slobodan Srećković
Cureus 2021
2

Publications

14 total

P1020 Association of Post-Induction Ustekinumab levels with treatment response in inflammatory bowel disease patients PDF

D Kralj, N Paravina, S Markovic, Tamara Knežević, M Jovanovic et al. - Journal of Crohn s and Colitis, 2026
Cited by 0 OpenAlex

Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease and ulcerative colitis: 2-year results from open-label extensions of two randomized controlled trials (LIBERTY) PDF

Jean–Frédéric Colombel, William J. Sandborn, Stefan Schreiber, Silvio Danese, Maria Kłopocka et al. - Journal of Crohn s and Colitis, 2025
Cited by 4 OpenAlex

Is Deep Remission the Right Time to De-Escalate Biologic Therapy in IBD? A Single-Center Retrospective Study PDF

Tamara Knežević Ivanovski, Milan Perović, Bojan Stopić, Olga Golubovic, Djordje Kralj et al. - Biomedicines, 2025
Cited by 2 OpenAlex

P1124 Disease Clearence after Acute Severe Ulcerative Colitis episode: is it possible ?

Srdjan Marković, Dominik Kralj, Miloš Mitrović, Tamara Knežević-Ivanovski, A Kalaba et al. - Journal of Crohn s and Colitis, 2025
Cited by 0 OpenAlex

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY) PDF

Stephen B. Hanauer, Bruce E. Sands, Stefan Schreiber, Silvio Danese, Maria Kłopocka et al. - Gastroenterology, 2024
Cited by 59 OpenAlex

P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study PDF

B E Sands, Stephen B. Hanauer, Jean‐Frédéric Colombel, William J. Sandborn, Stefan Schreiber et al. - Journal of Crohn s and Colitis, 2024
Cited by 2 OpenAlex

Su1779 SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) FOR ULCERATIVE COLITIS: 2-YEAR EXTENSION RESULTS OF THE LIBERTY-UC STUDY

William J. Sandborn, Bruce E. Sands, Stephen B. Hanauer, Jean‐Frédéric Colombel, Stefan Schreiber et al. - Gastroenterology, 2024
Cited by 0 OpenAlex

P838 Determing factors that influence Vedolizumab Response in Inflammatory Bowel Diseases: A Prospective Study PDF

Tamara Knežević, Aleksandar Dobrosavljević, O Odanovic, Slobodan Srećković, Dominik Kralj et al. - Journal of Crohn s and Colitis, 2024
Cited by 0 OpenAlex

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial PDF

Silvio Danese, Remo Panaccione, Brian G. Feagan, Anita Afzali, David T. Rubin et al. - ˜The œLancet. Gastroenterology & hepatology, 2023
Cited by 65 OpenAlex

P492 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study PDF

B E Sands, Stephen B. Hanauer, J F Colombel, William Sandborn, S Schreiber et al. - Journal of Crohn s and Colitis, 2023
Cited by 20 OpenAlex

Research Topics

Inflammatory Bowel Disease (12) Microscopic Colitis (11) Biosimilars and Bioanalytical Methods (4) Colorectal Cancer Treatments and Studies (2) Eosinophilic Esophagitis (2)

Frequent Co-Authors

JO
Joon Ho Lee
9 joint publications
SI
Silvio Danese
6 joint publications
WI
William J. Sandborn
6 joint publications
ST
Stephen B. Hanauer
6 joint publications
MA
Maria Kłopocka
6 joint publications
JA
Jarosław Kierkuś
6 joint publications

Affiliations

Kliničko Bolnički Centar Zvezdara
RS 2026 - 2020

External Profiles

OpenAlex Profile Semantic Scholar Profile Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now